About: Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor used in treatment of advanced NSCLC. Patients harboring EGFR or KRAS mutations represent minority of all patients in caucasian population and there is no available predictor for a predominant group of patients harboring the wild-type EGFR and wild-type KRAS genes. Skin rash is the most frequent manifestation of cutaneous toxicity of erlotinib. Rash is associated with a good therapeutic response. We aimed at the evaluation of rash as a predictor of therapeutic effect of erlotinib in patients harboring the wild-type EGFR and KRAS wild-type genes and to assess its possible usage in a clinical practice. Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor used in treatment of advanced NSCLC. Patients harboring EGFR or KRAS mutations represent minority of all patients in caucasian population and there is no available predictor for a predominant group of patients harboring the wild-type EGFR and wild-type KRAS genes. Skin rash is the most frequent manifestation of cutaneous toxicity of erlotinib. Rash is associated with a good therapeutic response. We aimed at the evaluation of rash as a predictor of therapeutic effect of erlotinib in patients harboring the wild-type EGFR and KRAS wild-type genes and to assess its possible usage in a clinical practice. (en)
Title	Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice (en)
skos:prefLabel	Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice (en)
skos:notation	RIV/00669806:_____/13:10140092!RIV14-MZ0-00669806
http://linked.open...avai/predkladatel	Fakultní nemocnice Plzeň
http://linked.open...avai/riv/aktivita	I P
http://linked.open...avai/riv/aktivity	I, P(NR9087)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Fiala, Ondřej Pešek, Miloš Říčař, Jan Fínek, Jindřich
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Plzeň
http://linked.open...dnocenehoVysledku	105410
http://linked.open...ai/riv/idVysledku	RIV/00669806:_____/13:10140092
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	skin toxicity; targeted traetment; rash; NSCLC; erlotinib (en)
http://linked.open.../riv/klicoveSlovo	targeted traetment rash NSCLC erlotinib skin toxicity
http://linked.open...odStatuVydavatele	SK - Slovenská republika
http://linked.open...ontrolniKodProRIV	[8214300AF407]
http://linked.open...i/riv/nazevZdroje	Neoplasma
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	4 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...vavai/riv/projekt	Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	60
http://linked.open...iv/tvurceVysledku	Benešová, Lucie Fiala, Ondřej Minárik, Marek Pešek, Miloš Krejčí, Jan Fínek, Jindřich Říčař, Jan Bortlíček, Zdeněk
http://linked.open...ain/vavai/riv/wos	000320086600004
issn	0028-2685
number of pages	7 (xsd:int)
http://bibframe.org/vocab/doi	10.4149/neo_2013_004

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 114 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software